CN108003199B - Enteromorpha oligosaccharide with blood sugar reducing function and preparation method and application thereof - Google Patents
Enteromorpha oligosaccharide with blood sugar reducing function and preparation method and application thereof Download PDFInfo
- Publication number
- CN108003199B CN108003199B CN201711454376.XA CN201711454376A CN108003199B CN 108003199 B CN108003199 B CN 108003199B CN 201711454376 A CN201711454376 A CN 201711454376A CN 108003199 B CN108003199 B CN 108003199B
- Authority
- CN
- China
- Prior art keywords
- enteromorpha
- oligosaccharide
- dry powder
- drying
- prolifera
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000196252 Ulva Species 0.000 title claims abstract description 107
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 96
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 96
- 238000002360 preparation method Methods 0.000 title claims description 19
- 239000008280 blood Substances 0.000 title abstract description 22
- 210000004369 blood Anatomy 0.000 title abstract description 22
- 230000001603 reducing effect Effects 0.000 title abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 16
- 235000013402 health food Nutrition 0.000 claims abstract description 13
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 13
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 76
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- 241000196253 Ulva prolifera Species 0.000 claims description 46
- 238000001694 spray drying Methods 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 25
- 239000002244 precipitate Substances 0.000 claims description 25
- 239000004365 Protease Substances 0.000 claims description 23
- 108090000526 Papain Proteins 0.000 claims description 21
- 229940055729 papain Drugs 0.000 claims description 21
- 235000019834 papain Nutrition 0.000 claims description 21
- 238000005406 washing Methods 0.000 claims description 21
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 239000012295 chemical reaction liquid Substances 0.000 claims description 11
- 238000000227 grinding Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 8
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 7
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 7
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 7
- 229930182830 galactose Natural products 0.000 claims description 7
- 229940097043 glucuronic acid Drugs 0.000 claims description 7
- 235000013361 beverage Nutrition 0.000 claims description 6
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 12
- 230000000593 degrading effect Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 43
- 241000699670 Mus sp. Species 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 11
- 150000004676 glycans Chemical class 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 6
- 229960001052 streptozocin Drugs 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000002144 chemical decomposition reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 206010036067 polydipsia Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 102000035101 Aspartic proteases Human genes 0.000 description 2
- 108091005502 Aspartic proteases Proteins 0.000 description 2
- 241000196319 Chlorophyceae Species 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 241000196246 Ulvaceae Species 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- -1 carbohydrate compounds Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 208000022530 polyphagia Diseases 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- BOSAWIQFTJIYIS-UHFFFAOYSA-N 1,1,1-trichloro-2,2,2-trifluoroethane Chemical compound FC(F)(F)C(Cl)(Cl)Cl BOSAWIQFTJIYIS-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 208000002230 Diabetic coma Diseases 0.000 description 1
- 241000195633 Dunaliella salina Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000220286 Sedum Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 241000196247 Ulvales Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000012851 eutrophication Methods 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses enteromorpha oligosaccharide with a blood sugar reducing function and an application method thereof. The enteromorpha oligosaccharide mixture with the hypoglycemic effect is prepared by degrading enteromorpha from Qingdao, has the efficacy of improving diabetes, and can be used as a pharmaceutical preparation or a health food for relieving type I diabetes in various ways or ways.
Description
Technical Field
The invention belongs to the technical field of health-care food and food, and particularly relates to enteromorpha oligosaccharide with a blood sugar reducing function, and a preparation method and application thereof.
Background
Diabetes is a metabolic disorder in which the body maintains high blood sugar levels for a long period of time, and typical symptoms are polyphagia, polydipsia, polyuria, and emaciation (more than three and one less). Diabetes, if not treated in time, can cause a variety of complications, which can be chronic, such as cardiovascular disease, stroke, chronic kidney disease, foot ulcers and eye damage, and acute, such as diabetic ketoacidosis, hypertonic non-ketotic diabetic coma, and even death. Diabetes is mainly classified according to etiology: (1) type I diabetes, where the pancreas produces little insulin; (2) type II diabetes, cells are insensitive to insulin response (insulin resistance). Type I diabetes is less studied and treatment is single relative to type II diabetes. Researches suggest that the type I diabetes is mainly an autoimmune reaction caused by combined action of a susceptible genetic factor and environmental factors such as food or microbial infection and the like, so that oxidative stress damage or apoptosis of islet beta cells is caused, the insulin secretion capacity of the islet beta cells is reduced, and the hyperglycemia expression is generated. At present, the most direct and effective treatment mode for the type I diabetes is to inject exogenous insulin, and the long-term injection of insulin greatly increases the dependence of the body on the insulin, thereby gradually reducing the drug effect of the insulin. Therefore, the development of an alternative medicine or health-care food with the function of reducing the blood sugar of the type I diabetes is particularly important, so that the treatment method of the type I diabetes is enriched, and the condition of a patient with the type I diabetes is promoted to be relieved.
Enteromorpha prolifera belongs to the genus Enteromorpha of the family Ulvaceae of the order Ulvales of the class Chlorophyceae. About 11 enteromorpha prolifera are widely distributed in the intertidal zone along the southeast of China, and due to the aggravation of seawater eutrophication in recent years, the excessively grown enteromorpha prolifera flows to coastal zones such as Qingdao and sunshine and is accumulated on the sea beach to flood and form a disaster, so that ecological balance and economic development are severely impacted. Meanwhile, the enteromorpha prolifera is used as edible and medicinal algae from ancient times, contains various active functional components, has high medicinal value and has great development potential. The enteromorpha polysaccharide component extracted from enteromorpha has a plurality of biological activities of enhancing the immunologic function, resisting tumors, diminishing inflammation, reducing blood sugar, reducing blood fat, resisting bacteria, resisting viruses and the like, but the development and the application of the biological activity of the enteromorpha polysaccharide are less at home and abroad. Researchers in China find that enteromorpha polysaccharide extracted by an alkaline method can obviously reduce the blood sugar concentration of mice with type I diabetes induced by alloxan, and the researchers do not give corresponding structural information.
At present, the following Chinese patent applications relate to the application of enteromorpha or derivatives thereof in reducing blood sugar:
CN102775512A
CN104068302A
CN105567762A
CN105695537A
CN106519059A
CN106819704A
in the currently disclosed enteromorpha-derived glycan patent, CN105567762A discloses that enteromorpha oligosaccharide degraded under the assistance of microwaves has the effect of reducing blood sugar, is only suitable for production and preparation of the oligosaccharide and is not suitable for extraction of glycan with larger molecular weight; CN105695537A discloses a glycosylated enteromorpha prolifera oligosaccharide for reducing blood sugar and regulating intestinal flora. The enteromorpha oligosaccharide between enteromorpha oligosaccharide and enteromorpha polysaccharide has no other reports or patents on the activity of reducing blood sugar and the application method thereof, but toxic reagents such as trichlorotrifluoroethane, trichloroacetic acid and the like are used in the protein removing process, so that the method is not suitable for the food production process, and the glycosylation process of the extracted oligosaccharide dunaliella salina also increases the production cost.
The enteromorpha prolifera oligosaccharide prepared in the Chinese patent application CN102775512A is steamed and refluxed for 4 hours by boiling water with the temperature of 100 ℃, so that the activity of polysaccharide is not favorably kept, and meanwhile, main products (mannose, fucose, glucose, galactose, arabinose and xylose) of the enteromorpha prolifera oligosaccharide are required to be improved in the aspect of blood sugar reducing effect.
The Chinese patent application CN106519059A adopts water boiling at 80-105 ℃ for 1-3 hours to process the substrate, and the temperature is high, which is not beneficial to retaining the activity of polysaccharide.
The Chinese patent application CN106819704A patent only has a warm water extraction step and lacks impurity removal steps, so that the components of the product are complex when different substrates are faced, and the product obtained by the method comprises small molecular peptides and non-carbohydrate compounds.
Disclosure of Invention
The invention provides enteromorpha oligosaccharide with a function of reducing blood sugar of type I diabetes and an application method thereof.
The invention provides enteromorpha oligosaccharide with the function of reducing blood sugar, which is prepared from the following raw materials: the enteromorpha prolifera salvaged in the Qingdao sea area is called Qingdao enteromorpha prolifera.
The invention provides enteromorpha oligosaccharide, which has the molecular weight of 1000 Da-10000 Da.
As a better choice of the enteromorpha prolifera oligosaccharide, the composition of the enteromorpha prolifera oligosaccharide comprises xylose, glucose, rhamnose, galactose and glucuronic acid.
As a better choice of the enteromorpha prolifera oligosaccharide, the molar ratio of xylose to glucose to rhamnose to galactose to glucuronic acid is 0.8-1.8: 1.6-2.4: 4.1-5.1: 0.46-0.87: 2.9-3.7.
The enteromorpha oligosaccharide provided by the invention is prepared according to the following method:
(1) providing a mixture of enteromorpha prolifera and water, wherein the mass ratio of the enteromorpha prolifera to the water in the mixture is 1: 15-30 percent of protease, and then adding 0.5-2 percent of protease to react for 4-6 hours at the temperature of 40-70 ℃ to obtain reaction liquid;
(2) filtering the reaction solution to obtain an extracting solution, and spray-drying the extracting solution at the temperature of 60-80 ℃ to obtain crude dry powder;
(3) and washing the crude dried powder by using a solvent, standing overnight to obtain a precipitate, and spray-drying to obtain the enteromorpha oligosaccharide dry powder.
Further, the degrading enzyme is papain.
As a better choice of the method, the enteromorpha prolifera is powder prepared by drying and grinding the raw material enteromorpha prolifera into powder.
Further, the solvent in step 3) is 75% ethanol.
Further, the enteromorpha oligosaccharide provided by the invention can be prepared according to the following method:
(1) providing a mixture of enteromorpha prolifera and water, wherein the mass ratio of the enteromorpha prolifera to the water in the mixture is 1: 15-30 percent, then adding 0.5-2 percent of degradation agent, and reacting for 4-6 hours at 40-70 ℃ to obtain reaction liquid;
(2) filtering the reaction solution to obtain an extracting solution, and spray-drying the extracting solution at the temperature of 60-80 ℃ to obtain crude dry powder;
(3) and washing the crude dry powder with 75% ethanol, standing overnight to obtain a precipitate, and spray drying to obtain the enteromorpha oligosaccharide dry powder.
The degradation agent can be an enzymatic degradation agent or a chemical degradation agent. The enzyme degradation agent can be papain, trypsin, chymotrypsin or aspartic protease. The chemical degradation agent can be hydrochloric acid, sulfuric acid, nitric acid or acetic acid.
Further, the enteromorpha oligosaccharide provided by the invention can be prepared according to the following method:
(1) providing a mixture of enteromorpha prolifera and water, wherein the mass ratio of the enteromorpha prolifera to the water in the mixture is 1: 15-30%, adding 0.5% -2% of papain, and reacting for 4-6 h at 40-70 ℃ to obtain a reaction solution;
(2) filtering the reaction solution to obtain an extracting solution, and spray-drying the extracting solution at the temperature of 60-80 ℃ to obtain crude dry powder;
(3) and washing the crude dry powder with 75% ethanol, standing overnight to obtain a precipitate, and spray drying to obtain the enteromorpha oligosaccharide dry powder.
As a better choice of the method, the enteromorpha prolifera is powder prepared by drying and grinding the raw material enteromorpha prolifera into powder.
Preferably, the enteromorpha oligosaccharide is prepared by the following method:
(1) providing a mixture of enteromorpha prolifera and water, wherein the mass ratio of the enteromorpha prolifera to the water in the mixture is 1: 20, adding 1% of papain, and reacting for 4 hours at 65 ℃ to obtain a reaction solution;
(2) filtering the reaction solution obtained in the step (1) to obtain an extracting solution, and spray-drying the extracting solution at the temperature of 60 ℃ to obtain crude extraction dry powder;
(3) and (3) washing the crude dried powder in the step (2) by using 75% ethanol, standing overnight to obtain a precipitate, and performing spray drying to obtain the enteromorpha oligosaccharide dry powder.
The invention also provides a clinically acceptable pharmaceutical preparation, health food or beverage prepared by adding conventional auxiliary materials into the enteromorpha prolifera oligosaccharide and adopting a conventional process.
The clinically acceptable preparation or health food comprises capsules, tablets, pills, granules, oral liquid, syrup, granules, dripping pills, powder, injection, tea, soft capsules, solid beverage, sustained and controlled release preparation, beverage and baked food.
The invention provides a method for preparing enteromorpha oligosaccharide pharmaceutical preparation or health food, which comprises the following steps:
(1) adding papain into a mixture of enteromorpha and water for reaction to obtain a reaction solution;
(2) filtering the reaction solution to obtain an extracting solution, and spray-drying the extracting solution to obtain crude extraction dry powder;
(3) and washing the crude dried powder with ethanol, standing overnight to obtain a precipitate, and spray drying to obtain the enteromorpha oligosaccharide dry powder.
The enteromorpha in the mixed solution can be powder prepared by drying and grinding the raw material enteromorpha.
Preferably, the method for preparing the enteromorpha oligosaccharide pharmaceutical preparation or the health food comprises the following steps:
(1) drying enteromorpha, grinding into powder, adding water, mixing uniformly, and adding papain to react to obtain a reaction solution;
(2) filtering the reaction solution to obtain an extracting solution, and spray-drying the extracting solution to obtain crude extraction dry powder;
(3) and washing the crude dried powder with ethanol, standing overnight to obtain a precipitate, and spray drying to obtain the enteromorpha oligosaccharide dry powder.
Further, the method may further comprise the steps of:
(4) conventional auxiliary materials are added into the enteromorpha oligosaccharide dry powder in the step (3), and a clinically acceptable pharmaceutical preparation or health food can be prepared according to a conventional process.
Preferably, the preparation method comprises the following steps:
(1) drying enteromorpha, grinding into powder, adding water with the weight being 18-32 times that of the enteromorpha, uniformly mixing, adding 0.4-1.5% of papain, and reacting at 45-70 ℃ for 4-6 h to obtain a reaction solution;
(2) filtering the reaction solution obtained in the step (1) to obtain an extracting solution, and spray-drying the extracting solution at the temperature of 60-70 ℃ to obtain crude extraction dry powder;
(3) washing the crude dried powder obtained in the step (2) by using 75% ethanol, standing overnight to obtain a precipitate, and performing spray drying to obtain enteromorpha oligosaccharide dry powder;
(4) and (3) adding conventional auxiliary materials into the enteromorpha oligosaccharide dry powder to prepare a clinically acceptable pharmaceutical preparation or health food.
More preferably, the preparation method comprises the following steps:
(1) drying enteromorpha, grinding into powder, adding water with the weight being 20 times that of the enteromorpha, uniformly mixing, adding 1% of papain, and reacting for 4 hours at the temperature of 65 ℃ to obtain reaction liquid;
(2) filtering the reaction solution obtained in the step (1) to obtain an extracting solution, and spray-drying the extracting solution at the temperature of 60 ℃ to obtain crude extraction dry powder;
(3) and washing the crude dry powder with 75% ethanol, standing overnight to obtain a precipitate, and spray drying to obtain the enteromorpha oligosaccharide dry powder.
(4) The enteromorpha oligosaccharide dry powder is added with conventional auxiliary materials to prepare clinically acceptable pharmaceutical preparations or health-care foods. The invention provides an application method of enteromorpha oligosaccharide in preparation of a medicinal preparation or a health-care food with a blood sugar reducing effect.
The invention also provides application of the enteromorpha oligosaccharide in preparing a medicinal preparation or health-care food for preventing and treating type I diabetes.
The raw material of the enteromorpha oligosaccharide is enteromorpha, also called as enteromorpha strip or sedum, belonging to the green algae phylum, Chlorophyceae, Ulvaceae and enteromorpha plants. The enteromorpha prolifera is rich in carbohydrates, proteins, crude fibers, amino acids, fatty acids, vitamins and various mineral substances. Is considered as a raw material of natural ideal nutritional food with high protein, high dietary fiber, low fat, low energy and rich minerals and vitamins. The enteromorpha polysaccharide component extracted from enteromorpha can enhance the immunologic function and improve the killing function on tumor cells, has a certain anti-inflammatory effect, and has better biological activity in the aspects of antibiosis and antivirus.
The enteromorpha oligosaccharide is obtained by degrading enteromorpha prolifera in Qingdao and has a good blood sugar reducing effect. Animal experiments prove that after the mice with type I diabetes induced by streptozotocin are administrated by enteromorpha oligosaccharide drinking water, after 1 month of treatment, the postprandial blood sugar level is obviously reduced, the symptoms of polydipsia, polydipsia and the like of the mice with diabetes can be obviously improved, the weight loss of the mice with diabetes is relieved to a certain degree, the weight loss of pancreatic organs of the mice with diabetes is improved to a certain degree, and the difference with statistical significance is shown by marks in a table. The experimental result indicates that the enteromorpha oligosaccharide has a good relieving effect on type I diabetes, and can be further used for development and application of health-care food or functional beverage.
Drawings
FIG. 1, molecular weight distribution of Enteromorpha oligosaccharides is identified by HPLC-GPC;
FIG. 2 illustrates the identification of monosaccharide composition of Enteromorpha oligosaccharide by capillary electrophoresis.
Detailed Description
The following are examples of the present invention, which are intended to be illustrative of the invention only and not limiting.
Example 1 Enteromorpha oligosaccharide preparation and structural characterization
In this example, enteromorpha oligosaccharide was prepared and structurally characterized. The specific implementation is as follows:
drying Enteromorpha prolifera with a certain mass, grinding into powder, adding water with the weight of 15-30 times of the Enteromorpha prolifera, uniformly mixing, adding 0.5-2% of papain, and reacting at 40-70 ℃ for 4-6 h to obtain a reaction solution; centrifuging the reaction liquid, taking the supernatant, and spray-drying the supernatant at the temperature of 60-80 ℃ to obtain crude dry powder. Washing the crude dry powder with 75% ethanol, centrifuging to obtain precipitate, and spray drying to obtain Enteromorpha oligosaccharide dry powder.
In the above process, papain is a degradation agent, which may also be an enzymatic degradation agent or a chemical degradation agent. The enzyme degradation agent can be trypsin, chymotrypsin or aspartic protease, and the chemical degradation agent can be hydrochloric acid, sulfuric acid, nitric acid or acetic acid. When using chemical degradation agents, food grade materials are preferably used, and the concentration thereof is controlled to reduce the corresponding side reactions, and the person skilled in the art can control the degradation process in real time in combination with the prior art.
The molecular weight distribution of the enteromorpha oligosaccharide is characterized by an HPLC-GPC method, and the molecular weight range of the enteromorpha oligosaccharide is determined to be 400 Da-15000 Da (see figure 1).
The composition of the corresponding oligosaccharides is shown in the following table:
| time of day | Peak area | Peak height | Peak width | Symmetry factor | Peak area% | Area％ | logMw | Molecular weight Da | |
| 1 | 11.302 | 1714970.9 | 42503.5 | 0.6725 | 0.402 | 41.305 | 41.305 | 4.1331222 | 13586.95697 |
| 2 | 12.468 | 1791377.6 | 21022.3 | 1.4202 | 0.418 | 43.145 | 43.145 | 3.8370748 | 6871.867863 |
| 3 | 16.963 | 645634.4 | 33468.6 | 0.3215 | 1.999 | 15.55 | 15.55 | 2.6957943 | 496.3571703 |
The monosaccharide composition of the enteromorpha oligosaccharide is determined by a capillary electrophoresis method, and the components of the enteromorpha oligosaccharide are determined to comprise xylose, glucose, rhamnose, galactose and glucuronic acid, wherein the rhamnose and the glucuronic acid are main components of the enteromorpha oligosaccharide, and the specific composition can be seen in the following table:
| monosaccharide composition | Molar ratio of | Mole percent (%) |
| Xylose | 1.00 | 8.99 |
| Glucose | 2.07 | 18.3 |
| Rhamnose | 4.16 | 36.8 |
| Galactose | 0.46 | 4.1 |
| Glucuronic acid | 3.60 | 31.9 |
The invention also obtains enteromorpha oligosaccharide with the following composition by changing the preparation method, which is concretely the enteromorpha oligosaccharide
Example 2 hypoglycemic Effect of Enteromorpha oligosaccharides
(1) In the experimental example, in order to evaluate the hypoglycemic effect of enteromorpha oligosaccharide on type I diabetic mice, 24 four-week-old C57BL/6 mice were randomly divided into 4 groups, each of which was 6, and the groups respectively corresponded to a normal treatment group, a streptozotocin stimulation group, an enteromorpha oligosaccharide treatment group, an enteromorpha oligosaccharide and streptozotocin stimulation combined group, and the like. Mice were housed in a constant temperature, humidity environment for a 1 week acclimation period. Mice were intraperitoneally injected with streptozotocin at a dose of 50mg per kg body weight per day (50mg/kg/d) for 5 consecutive days corresponding to the streptozotocin stimulated group.
(2) Within 3 weeks of streptozotocin injected mice, islet beta cells are destroyed and blood glucose rises sharply, thereby creating a mouse model of type I diabetes that exhibits symptoms of polydipsia, polyphagia, polyuria, and wasting (i.e., more than three and one less).
(3) In the 6 th week, 1g/L enteromorpha oligosaccharide (dissolved in water and administered by drinking water) is used for treating the corresponding mice for 1 month, and the diabetes indexes such as diet, drinking water, weight change, blood sugar level and the like of the treated mice are detected. As shown in Table 1, the water intake, food intake and blood sugar level of the mice of the diabetes model are obviously increased, and the diabetes index is obviously improved after the mice are treated by the enteromorpha oligosaccharide.
TABLE 1 changes in diabetic symptoms in groups after animal experiments: (*p<0.05，**p<The normal group of 0.01vs,#p<0.05vs model group)
Example 3 application method of Enteromorpha oligosaccharides
(1) Capsule preparation
a. Taking 10kg of Enteromorpha prolifera of Qingdao, adding water with the weight being 20 times that of the raw materials for extracting, then adding 1% of papain, and reacting for 4 hours at the temperature of 65 ℃ to obtain reaction liquid;
b. obtaining an extracting solution, and spray-drying the extracting solution at 65 ℃ to obtain crude dry powder.
c. And b, washing the crude dried powder in the step b by using 75% ethanol, standing overnight to obtain a precipitate, and spray-drying to obtain the enteromorpha oligosaccharide dry powder.
d. And c, adding a proper amount of conventional auxiliary materials into the enteromorpha prolifera oligosaccharide dry powder, uniformly mixing, freeze-drying, crushing, filling capsules, and subpackaging to obtain the enteromorpha prolifera oligosaccharide dry powder.
(2) Tablet formulation
a. Taking 10kg of Enteromorpha prolifera of Qingdao, adding water with weight being 25 times of that of the raw materials for extracting, then adding 1% of papain, and reacting for 4 hours at 65 ℃ to obtain reaction liquid;
b. obtaining an extracting solution, and spray-drying the extracting solution at 65 ℃ to obtain crude dry powder.
c. And c, washing the crude dry powder in the step b by using 75% ethanol, and standing overnight to obtain a precipitate.
d. Adding appropriate amount of conventional adjuvants into the precipitate, mixing, granulating by high speed wet method, boiling at 60 deg.C, drying, tabletting, and packaging.
(3) Granules
a. Taking 10kg of Enteromorpha prolifera of Qingdao, adding water with weight being 25 times of that of the raw materials for extracting, then adding 1% of papain, and reacting for 4 hours at 65 ℃ to obtain reaction liquid;
b. obtaining an extracting solution, and spray-drying the extracting solution at 65 ℃ to obtain crude dry powder.
c. Washing the crude dry powder with 75% ethanol, standing overnight to obtain precipitate.
d. Adding appropriate amount of conventional adjuvants into the precipitate, mixing, sieving with 20 mesh sieve, extruding, granulating, boiling at 60 deg.C, drying, and packaging.
(4) Oral liquid
a. Taking 10kg of Enteromorpha prolifera of Qingdao, adding water with weight being 25 times of that of the raw materials for extracting, then adding 1% of papain, and reacting for 4 hours at 65 ℃ to obtain reaction liquid;
b. obtaining an extracting solution, and spray-drying the extracting solution at 65 ℃ to obtain crude dry powder.
c. Washing the crude dry powder with 75% ethanol, standing overnight to obtain precipitate.
d. Adding water, appropriate amount of correctant and antiseptic into the precipitate, mixing, making into solution, bottling, and sterilizing.
(5) Solid beverage
a. Taking 10kg of Enteromorpha prolifera of Qingdao, adding water with weight being 25 times of that of the raw materials for extracting, then adding 1% of papain, and reacting for 4 hours at 65 ℃ to obtain reaction liquid;
b. obtaining an extracting solution, and spray-drying the extracting solution at 65 ℃ to obtain crude dry powder.
c. Washing the crude dry powder with 75% ethanol, standing overnight to obtain precipitate.
d. Adding appropriate amount of conventional adjuvants into the precipitate, mixing, spray drying, and packaging.
(6) Biscuit
a. Taking 10kg of Enteromorpha prolifera of Qingdao, adding water with weight being 25 times of that of the raw materials for extracting, then adding 1% of papain, and reacting for 4 hours at 65 ℃ to obtain reaction liquid;
b. obtaining an extracting solution, and spray-drying the extracting solution at 65 ℃ to obtain crude dry powder.
c. Washing the crude dry powder with 75% ethanol, centrifuging, removing supernatant, washing with 75% ethanol again, standing for precipitation to obtain precipitate.
d. Adding appropriate amount of conventional adjuvants into the precipitate, mixing, and making into biscuit acceptable for food according to conventional process.
It should be understood that the above examples are only for illustrative clarity and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. This need not be, nor should it be exhaustive of all embodiments. And obvious variations or modifications of the invention may be made without departing from the spirit or scope of the invention.
Claims (14)
1. The enteromorpha oligosaccharide is characterized in that the composition of the molecular weight of the enteromorpha oligosaccharide is 1000 Da-10000 Da;
the enteromorpha prolifera oligosaccharide comprises xylose, glucose, rhamnose, galactose and glucuronic acid, and the molar ratio of the enteromorpha prolifera oligosaccharide is 0.8-1.8: 1.6-2.4: 4.1-5.1: 0.46-0.87: 2.9-3.7;
the enteromorpha oligosaccharide is prepared by the following method:
(1) providing a mixture of enteromorpha prolifera and water, wherein the mass ratio of the enteromorpha prolifera to the water in the mixture is 1: 15-30%, adding 0.5% -2% of papain, and reacting for 4-6 h at 40-70 ℃ to obtain a reaction solution;
(2) filtering the reaction solution to obtain an extracting solution, and spray-drying the extracting solution at the temperature of 60-80 ℃ to obtain crude dry powder;
(3) and washing the crude dry powder, standing overnight to obtain a precipitate, and spray drying to obtain the enteromorpha oligosaccharide dry powder.
2. The enteromorpha oligosaccharide according to claim 1, wherein the raw material for preparing the enteromorpha oligosaccharide is enteromorpha in Qingdao sea area.
3. The enteromorpha oligosaccharide according to claim 1, wherein the enteromorpha oligosaccharide is prepared by the following method:
(1) providing a mixture of enteromorpha prolifera and water, wherein the mass ratio of the enteromorpha prolifera to the water in the mixture is 1: 20, adding 1% of papain, and reacting for 4 hours at 65 ℃ to obtain a reaction solution;
(2) filtering the reaction solution obtained in the step (1) to obtain an extracting solution, and performing spray drying on the extracting solution at the temperature of 60 ℃ to obtain crude dry powder;
(3) and (3) washing the crude dried powder in the step (2) by using 75% ethanol, standing overnight to obtain a precipitate, and performing spray drying to obtain the enteromorpha oligosaccharide dry powder.
4. A clinically acceptable pharmaceutical formulation characterized by: the pharmaceutical preparation contains the enteromorpha oligosaccharide as claimed in any one of claims 1-3.
5. A clinically acceptable health food characterized by: the health food contains the enteromorpha oligosaccharide as claimed in any one of claims 1 to 3.
6. A clinically acceptable beverage characterized by: the beverage contains the enteromorpha oligosaccharide as claimed in any one of claims 1-3.
7. A method for preparing enteromorpha oligosaccharide comprises the following steps:
(1) drying enteromorpha, grinding into powder, adding water, mixing uniformly, and adding papain to react to obtain a reaction solution;
(2) filtering the reaction solution to obtain an extracting solution, and spray-drying the extracting solution to obtain crude extraction dry powder;
(3) washing the crude dried powder with ethanol, standing overnight to obtain a precipitate, and spray drying to obtain enteromorpha oligosaccharide dry powder;
the composition of the molecular weight of the enteromorpha oligosaccharide is 1000 Da-10000 Da;
the enteromorpha prolifera oligosaccharide comprises xylose, glucose, rhamnose, galactose and glucuronic acid, and the molar ratio of the enteromorpha prolifera oligosaccharide is 0.8-1.8: 1.6-2.4: 4.1-5.1: 0.46-0.87: 2.9-3.7.
8. The method of claim 7, further comprising the steps of:
(4) after the conventional auxiliary materials are added into the enteromorpha prolifera oligosaccharide dry powder, a clinically acceptable pharmaceutical preparation or health food is prepared.
9. The method according to claim 7 or 8, wherein the preparation method of the enteromorpha oligosaccharide comprises the following steps:
(1) drying enteromorpha, grinding into powder, adding water with the weight being 18-32 times that of the enteromorpha, uniformly mixing, adding 0.4-1.5% of papain, and reacting at 45-70 ℃ for 4-6 h to obtain a reaction solution;
(2) filtering the reaction solution obtained in the step (1) to obtain an extracting solution, and spray-drying the extracting solution at the temperature of 60-70 ℃ to obtain crude extraction dry powder;
(3) washing the crude dried powder obtained in the step (2) by using 75% ethanol, standing overnight to obtain a precipitate, and performing spray drying to obtain enteromorpha oligosaccharide dry powder;
(4) and (3) adding conventional auxiliary materials into the enteromorpha oligosaccharide dry powder to prepare a clinically acceptable pharmaceutical preparation or health food.
10. The method according to claim 9, wherein the preparation method of enteromorpha oligosaccharide comprises the following steps:
(1) drying enteromorpha, grinding into powder, adding water with the weight being 20 times that of the enteromorpha, uniformly mixing, adding 1% of papain, and reacting for 4 hours at the temperature of 65 ℃ to obtain reaction liquid;
(2) filtering the reaction solution obtained in the step (1) to obtain an extracting solution, and performing spray drying on the extracting solution at the temperature of 60 ℃ to obtain crude dry powder;
(3) washing the crude dry powder with 75% ethanol, standing overnight to obtain a precipitate, and spray drying to obtain enteromorpha oligosaccharide dry powder;
(4) the enteromorpha oligosaccharide dry powder is added with conventional auxiliary materials to prepare clinically acceptable pharmaceutical preparations or health-care foods.
11. Use of the enteromorpha oligosaccharide in any one of claims 1-3 in the preparation of a pharmaceutical preparation with hypoglycemic effect.
12. Use of the enteromorpha oligosaccharide in any one of claims 1-3 in preparation of health food with hypoglycemic effect.
13. Use of the enteromorpha oligosaccharide as claimed in any one of claims 1-3 in the preparation of a pharmaceutical preparation for preventing and treating type I diabetes.
14. Use of the enteromorpha oligosaccharide as claimed in any one of claims 1-3 in preparation of health food for preventing and treating type I diabetes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710565514 | 2017-07-12 | ||
| CN2017105655145 | 2017-07-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108003199A CN108003199A (en) | 2018-05-08 |
| CN108003199B true CN108003199B (en) | 2020-08-18 |
Family
ID=62062057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711454376.XA Active CN108003199B (en) | 2017-07-12 | 2017-12-28 | Enteromorpha oligosaccharide with blood sugar reducing function and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108003199B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109734761A (en) * | 2019-02-28 | 2019-05-10 | 福建农林大学 | A kind of preparation method and applications of Enteromorpha fucose complex compound |
| CN110179117A (en) * | 2019-07-15 | 2019-08-30 | 青岛瑞思德生物科技有限公司 | A kind of hypoglycemic particle electuary and preparation method thereof |
| CN113121714B (en) * | 2021-03-16 | 2022-08-23 | 浙江工业大学 | Ganoderma lucidum oligosaccharide with probiotic activity and preparation method and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103804503A (en) * | 2012-11-13 | 2014-05-21 | 烟台大学 | Method of extracting polysaccharide of enteromorpha by enzymolysis in steps |
| CN103044570B (en) * | 2013-01-25 | 2015-08-26 | 福建海兴保健食品有限公司 | A kind of extraction process of high efficiency extraction sea grass polysaccharide |
| CN104068302A (en) * | 2013-03-29 | 2014-10-01 | 烟台大学 | Enteromorpha polysaccharide oral liquid and preparation method thereof |
| CN103333267A (en) * | 2013-07-12 | 2013-10-02 | 青岛王牌动物健康产品有限公司 | Enteromorpha se-polysaccharide with biological activity as well as preparation method and application of enteromorpha se-polysaccharide |
| CN105294871B (en) * | 2015-09-25 | 2018-06-22 | 广东医学院 | A kind of preparation method and application with enhancing immune function sea grass polysaccharide |
| CN106282266B (en) * | 2016-08-21 | 2019-12-20 | 青岛海大生物集团有限公司 | Method for preparing enteromorpha prolifera oligosaccharide by using naringinase |
-
2017
- 2017-12-28 CN CN201711454376.XA patent/CN108003199B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108003199A (en) | 2018-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108003199B (en) | Enteromorpha oligosaccharide with blood sugar reducing function and preparation method and application thereof | |
| CN103734751B (en) | A kind of composite dietary and method for making thereof | |
| CN101023967B (en) | Compound extract of common phellinus fungus and chaga, its preparing method and preparation | |
| CN108785342B (en) | Moringa oleifera leaf extract with hypoglycemic activity and preparation method thereof | |
| CN104026446A (en) | Nutritional meal replacement powder suitable for crowd with hyperglycemia and preparation method thereof | |
| CN110201067B (en) | Ampelopsis grossedentata extract and preparation method and application thereof | |
| CN103768152A (en) | Osmanthus phenylethanoid glycoside extract, and preparation method and application thereof | |
| CN107184966A (en) | A kind of pharmaceutical composition for preventing and treating diabetes and its complication | |
| CN112961262A (en) | Passiflora edulis pericarp acidic polysaccharide, preparation method and application thereof | |
| KR101182824B1 (en) | Composition having anti-allergic activity containing Zanthoxylum piperitum DC fruit extract or glycoprotein isolated from its extract | |
| JP2010202580A (en) | alpha-GLUCOSIDASE INHIBITOR DERIVED FROM NATURAL MATERIAL | |
| CN101450101A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| KR20160006812A (en) | Compositions for preventing and curing diabetes comprising extract of Paeonia lactiflora | |
| KR20210012979A (en) | Levan-protein nanocomposite and uses thereof | |
| KR20110045371A (en) | Composition comprising extracts of Radix Smilax china, Paecilomyces japonica and Momordica charantia for hypoglycemic agent] | |
| CN110218262A (en) | Application of the low sulphated heteroglycan rich in glucuronic acid in brown alga source in preparation treatment diabetes B drug | |
| KR102181220B1 (en) | Pharmaceutical composition for anti-cancer containing medicinal gerb extracts | |
| CN101491668B (en) | Composition with blood-sugar reducing function and preparation method thereof | |
| KR101695488B1 (en) | Composition for preventing and improving of diarrohea, and oral syringe package using the same | |
| CN111803559B (en) | Eggplant peel composition with blood sugar reducing effect and preparation method and application thereof | |
| CN101366731B (en) | Propolis flavone, preparation method and uses in treating diabetes | |
| CN109420157A (en) | A kind of application of pharmaceutical composition | |
| CN103768294A (en) | Medical application of colocasia tonoimo nakia and stem leaves thereof in preventing and treating diabetes | |
| CN115814007B (en) | Alpha-glucosidase inhibitor and preparation method and application thereof | |
| CN101491580A (en) | Combination with blood sugar reducing function and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |